CN101309917B - 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 - Google Patents

具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 Download PDF

Info

Publication number
CN101309917B
CN101309917B CN2006800426099A CN200680042609A CN101309917B CN 101309917 B CN101309917 B CN 101309917B CN 2006800426099 A CN2006800426099 A CN 2006800426099A CN 200680042609 A CN200680042609 A CN 200680042609A CN 101309917 B CN101309917 B CN 101309917B
Authority
CN
China
Prior art keywords
compound
enantiomorph
weight
mixture
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800426099A
Other languages
English (en)
Chinese (zh)
Other versions
CN101309917A (zh
Inventor
托马斯·甘特
赛博·萨莎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auspex Pharmaceuticals Inc
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101309917(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CN101309917A publication Critical patent/CN101309917A/zh
Application granted granted Critical
Publication of CN101309917B publication Critical patent/CN101309917B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2006800426099A 2005-10-06 2006-10-04 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 Active CN101309917B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72416005P 2005-10-06 2005-10-06
US60/724,160 2005-10-06
US74131605P 2005-12-01 2005-12-01
US60/741,316 2005-12-01
PCT/US2006/038819 WO2007041630A1 (en) 2005-10-06 2006-10-04 Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties

Publications (2)

Publication Number Publication Date
CN101309917A CN101309917A (zh) 2008-11-19
CN101309917B true CN101309917B (zh) 2013-09-11

Family

ID=37603090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800426099A Active CN101309917B (zh) 2005-10-06 2006-10-04 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂

Country Status (9)

Country Link
US (3) US7598273B2 (enExample)
EP (1) EP1934201A1 (enExample)
JP (1) JP2009511481A (enExample)
CN (1) CN101309917B (enExample)
AU (1) AU2006299424A1 (enExample)
BR (1) BRPI0617987A2 (enExample)
CA (1) CA2624179A1 (enExample)
IL (1) IL190331A0 (enExample)
WO (1) WO2007041630A1 (enExample)

Families Citing this family (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683177B2 (en) * 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
JP5301991B2 (ja) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
EP2194039A1 (en) * 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
WO2007140189A2 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
WO2008024439A2 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
JP2010507593A (ja) * 2006-10-20 2010-03-11 コンサート ファーマシューティカルズ インコーポレイテッド ３−（ジヒドロ−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−５−イル）−４−プロポキシベンゼンスルホンアミド誘導体および使用方法
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
US20080280927A1 (en) * 2006-10-20 2008-11-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
EP2099299A4 (en) * 2006-10-23 2011-11-30 Concert Pharmaceuticals Inc OXAZOLIDINONE DERIVATIVES AND METHOD FOR THEIR USE
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
US20100260674A1 (en) * 2006-12-15 2010-10-14 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US8343950B2 (en) * 2006-12-15 2013-01-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US20090325976A1 (en) * 2006-12-21 2009-12-31 Concert Pharmaceuticals Inc. Prostacyclin derivatives
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) * 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
EP2118073A2 (en) * 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
EP2125717B1 (en) * 2007-02-26 2013-07-03 Concert Pharmaceuticals Inc. Deuterated derivatives of silodosin as alpha ia-adrenoreceptor antagonists
ATE509015T1 (de) * 2007-03-07 2011-05-15 Concert Pharmaceuticals Inc Deuterierte piperazinderivate als verbindungen gegen angina
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008127640A2 (en) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008130863A2 (en) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US8349817B2 (en) 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
US7608737B2 (en) * 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
EP3093290B1 (en) 2007-05-01 2018-01-24 Concert Pharmaceuticals Inc. Morphinan compounds
ES2401892T3 (es) 2007-05-01 2013-04-25 Concert Pharmaceuticals Inc. Compuestos morfinanos
US7820666B2 (en) * 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
US20080306151A1 (en) * 2007-06-11 2008-12-11 Protia, Llc Deuterium-enriched fenofibrate
SI2003120T1 (sl) 2007-06-12 2010-03-31 Concert Pharmaceuticals Inc Azapeptidni derivati kot inhibitorji hiv proteaze
CA2690379A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090005366A1 (en) * 2007-06-19 2009-01-01 Protia, Llc Deuterium-enriched olanzapine
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
US20080319007A1 (en) * 2007-06-21 2008-12-25 Protia, Llc Deuterium-enriched montelukast
US7687509B2 (en) * 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
CN101821260B (zh) 2007-08-14 2013-07-31 康塞特医药品有限公司 取代的噁唑烷酮衍生物
US20090062283A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched linezolid
US20090062393A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pregabalin
US20090062305A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched cetirizine
US20090062316A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched pelitrexol
US20090062385A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched fesoterodine
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
US20090062561A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched latanoprost
US20090062299A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched doxazosin
US20090062374A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched lasofoxifene
US20090069410A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched paclitaxel
US20090069413A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched olopatadine
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090069339A1 (en) * 2007-09-11 2009-03-12 Protia, Llc Deuterium-enriched ciprofloxacin
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
EP2197847B1 (en) * 2007-09-12 2012-11-07 Concert Pharmaceuticals Inc. Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection
US20090076165A1 (en) * 2007-09-12 2009-03-19 Protia, Llc Deuterium-enriched memantine
US20090076118A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched saxagliptin
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US20090076112A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched eltrombopag
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090075965A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched amoxicilin
US7919516B2 (en) * 2007-09-13 2011-04-05 Protia, Llc Deuterium-enriched ondansetron
US20090076161A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched bupropion
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
US20090076102A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched muraglitazar
US20090075991A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched efavirenz
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
US20090076148A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched pravastatin
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
US20090075944A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ibandronate
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
US20090076028A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched itraconazole
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
US20090076040A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched valganciclovir
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
US20090076163A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched dapoxetine
US20090076126A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched enalapril
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
US20090076154A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched vorinostat
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
US20090075997A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched satavaptan
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
US20090076159A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
US20090076011A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched tirapazamine
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
US20090082459A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched guanfacine
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US20090082335A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched oxcarbazepine
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
WO2009051747A1 (en) * 2007-10-15 2009-04-23 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
AU2008317375B2 (en) * 2007-10-26 2013-02-28 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US20090175824A1 (en) * 2007-11-20 2009-07-09 Craig Masse Peptides for the treatment of HCV infections
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
EP2231155A4 (en) * 2007-12-18 2011-09-14 Concert Pharmaceuticals Inc Tetrahydroisoquinoline DERIVATIVES
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
CN101492452B (zh) * 2008-01-25 2010-11-17 山东轩竹医药科技有限公司 含有二氧杂环庚烷并吡啶的巯基苯并咪唑衍生物
CN101492464B (zh) * 2008-01-25 2011-01-12 山东轩竹医药科技有限公司 含有二氧杂环庚烷并吡啶的巯基咪唑并吡啶衍生物
WO2009105604A1 (en) * 2008-02-20 2009-08-27 Auspex Pharmaceuticals, Inc. Substituted triazolopyridines
EP2265334A2 (en) * 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CA2715036A1 (en) * 2008-03-14 2009-09-17 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
WO2009114814A2 (en) 2008-03-14 2009-09-17 Retrotope, Inc. Therapeutic substances that modulate genome methylation
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
JP2011518783A (ja) * 2008-04-09 2011-06-30 コンサート ファーマシューティカルズ インコーポレイテッド ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法
US8367674B2 (en) * 2008-04-17 2013-02-05 Concert Pharmaceuticals, Inc. Piperazine derivatives
US20110129549A1 (en) * 2008-04-17 2011-06-02 Liu Julie F Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
US20100120786A1 (en) * 2008-04-17 2010-05-13 Concert Pharmaceuticals, Inc. Piperazine Derivatives
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US8354557B2 (en) * 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
PL2328414T3 (pl) 2008-08-29 2014-05-30 Concert Pharmaceuticals Inc Podstawione pochodne triazolo-pirydazyny
US8541419B2 (en) * 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
CA2736091A1 (en) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
US20100105755A1 (en) * 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
EP2334621A1 (en) * 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2010033270A1 (en) * 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
ES2750825T3 (es) 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
US20100087455A1 (en) * 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
JP5706825B2 (ja) 2008-10-17 2015-04-22 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. フェノール性オピオイドの放出が減弱された医薬組成物
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US20100137215A1 (en) * 2008-11-25 2010-06-03 Concert Pharmaceuticals Inc. Novel tetrahydro-1h-pyrido[4,3-b]indoles
WO2010065755A1 (en) * 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20100143354A1 (en) * 2008-12-04 2010-06-10 Auspex Pharmaceuticals, Inc. Triazine dna modifiers
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US8765953B2 (en) * 2008-12-23 2014-07-01 Aquilus Pharmaceuticals, Inc. Compounds and methods for the treatment of pain and other diseases
EP2396312A1 (en) * 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US20110053961A1 (en) * 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US8778998B2 (en) * 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US20100291151A1 (en) * 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
BRPI1014669A2 (pt) 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US20100305173A1 (en) * 2009-04-30 2010-12-02 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2010135579A1 (en) 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CN102459180B (zh) * 2009-06-09 2014-05-14 江苏迈度药物研发有限公司 作为激酶抑制剂的脲衍生物
EP3090999A1 (en) 2009-06-18 2016-11-09 Concert Pharmaceuticals Inc. Deuterated isoindoline-1, 3-dione derivatives as pde4 and tnf-alpha inhibitors
EP2454259A1 (en) * 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
CA2768368A1 (en) * 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
WO2011011712A1 (en) * 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8637524B2 (en) * 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US8618116B2 (en) * 2009-08-03 2013-12-31 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
WO2011020044A1 (en) * 2009-08-14 2011-02-17 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
US8658236B2 (en) 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
EP2473052A4 (en) * 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc SUBSTITUTED XANTHINE DERIVATIVES
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
WO2011047315A1 (en) * 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
KR20120092142A (ko) * 2009-10-28 2012-08-20 애나디스 파마슈티칼스, 인코포레이티드 중수소화 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물
WO2011060112A1 (en) 2009-11-12 2011-05-19 Osi Pharmaceuticals, Inc. Deuterated tyrosine kinase inhibitors
US8471034B2 (en) * 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
EP2501679A1 (en) * 2009-11-21 2012-09-26 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
US20110178180A1 (en) * 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20110206661A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
CA2790707A1 (en) * 2010-03-01 2011-09-09 Concert Pharmaceuticals Inc. Fluorouracil derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011109464A1 (en) * 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
WO2011133150A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
BR112012026768A2 (pt) * 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
AU2011298382A1 (en) * 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
BR112013017296B1 (pt) 2011-01-11 2021-02-17 Signature Therapeutics, Inc. composto e composição compreendendo oxicodona, método para reduzir o abuso potencial da referida composição, unidade de dose e método para a sua preparação, e método para identificar um composto e um inibidor de tripsina
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US20130310396A1 (en) * 2011-01-19 2013-11-21 Hongwen Zhu Thiazolidine derivatives and their therapeutic use
US8759394B2 (en) 2011-02-14 2014-06-24 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US8889687B2 (en) 2011-03-04 2014-11-18 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
AU2012250776B2 (en) * 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP6386382B2 (ja) * 2012-02-08 2018-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 卵胞刺激ホルモン受容体のアゴニストとしての重水素化されたチアゾリジノン類似体
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
SMT202500302T1 (it) * 2012-06-15 2025-09-12 Sun Pharmaceutical Industries Inc Derivati deuterati del ruxolitinib
US9181190B2 (en) 2012-07-04 2015-11-10 Concert Pharmaceuticals, Inc. Deuterated vercirnon
EP2885267B1 (en) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuterated idebenone
IN2015DN00598A (enExample) 2012-07-30 2015-06-26 Concert Pharmaceuticals Inc
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
US20150210624A1 (en) * 2012-08-22 2015-07-30 Concert Pharmaceuticals, Inc. Deuterated 4-hydroxybutyric acid analogs
US9682952B2 (en) 2012-09-04 2017-06-20 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
KR20150053906A (ko) * 2012-09-07 2015-05-19 액시킨 파마수티컬스 인코포레이티드 동위원소 농축 아릴설폰아미드 ccr3 길항제
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
EP2943489B1 (en) 2013-01-09 2018-04-11 Concert Pharmaceuticals Inc. Deuterated momelotinib
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014121036A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CN103204819B (zh) * 2013-04-15 2015-03-11 公安部物证鉴定中心 氘代地西泮及其制备方法
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
EP3076967B1 (en) 2013-12-03 2021-07-28 Intra-Cellular Therapies, Inc. Methods for treating residual symptoms of schizophrenia
CA2932757C (en) * 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015095713A1 (en) 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US9884872B2 (en) * 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
IL285760B2 (en) * 2014-09-02 2025-03-01 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
CA2966452A1 (en) * 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
CA2981365A1 (en) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as atm kinase inhibitors
US10683305B2 (en) * 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CN107698620A (zh) * 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
KR102457316B1 (ko) * 2015-06-26 2022-10-20 총킹 디캉 에릴 파마 씨오. 엘티디. 새로운 5형포스포디에스테라아제 억제제 및 그 용도
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017053711A2 (en) 2015-09-25 2017-03-30 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
CN107207469B (zh) * 2015-10-21 2018-09-25 纽弗姆制药有限公司 用于治疗血液恶性肿瘤的氘代化合物以及其组合物和方法
US20200262800A1 (en) * 2015-11-16 2020-08-20 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
CN108541255B (zh) * 2016-02-02 2019-06-14 深圳市塔吉瑞生物医药有限公司 一种甾体类化合物及包含该化合物的组合物及其用途
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX387784B (es) 2017-03-24 2025-03-18 Intra Celular Therapies Inc Composiciones novedosas y metodos.
WO2018213426A1 (en) * 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CN109498811A (zh) * 2017-09-15 2019-03-22 江苏吉贝尔药业股份有限公司 一种含钾离子竞争性酸阻滞剂和非甾体抗炎药的复方制剂
JP7518765B2 (ja) 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
CN111479804B (zh) 2017-12-01 2023-12-22 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
US11453672B2 (en) * 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
CN111848622A (zh) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
JP7710223B2 (ja) * 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2019246085A1 (en) * 2018-06-19 2019-12-26 Celecor Therapeutics, Inc. Deuterated ruc-4
EP3816162A4 (en) * 2018-07-12 2021-08-11 Shenzhen TargetRx, Inc. DIARYL PYRAZOLE COMPOUND, COMPOSITION THEREOF, AND USE THEREOF
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
CN108752322A (zh) * 2018-09-12 2018-11-06 广州新民培林医药科技有限公司 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用
CN118806924A (zh) * 2018-09-26 2024-10-22 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
WO2020206367A1 (en) 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
WO2020227491A1 (en) * 2019-05-07 2020-11-12 The Trustees Of The University Of Pennsylvania Deuterated triazolopyrimidines
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
CN110194773B (zh) * 2019-07-26 2019-11-22 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
EP4413980A3 (en) * 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
WO2023092044A2 (en) 2021-11-17 2023-05-25 Terran Biosciences, Inc. Phenethylamine compounds salts, polymorphic forms and methods of use thereof
TW202325301A (zh) * 2021-12-14 2023-07-01 大陸商海思科醫藥集團股份有限公司 三環稠雜環類pde3/4雙重抑制及其用途
WO2023147419A2 (en) * 2022-01-27 2023-08-03 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
CN116726011A (zh) * 2022-03-04 2023-09-12 丽珠医药集团股份有限公司 艾普拉唑用于调节消化道微生态的用途
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268051A (zh) * 2005-07-26 2008-09-17 尼科梅德有限责任公司 同位素取代的质子泵抑制剂
CN101268050A (zh) * 2005-07-26 2008-09-17 尼科梅德有限责任公司 同位素取代的泮托拉唑

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ATE114114T1 (de) * 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
DE69840586D1 (de) * 1997-10-08 2009-04-02 Isotechnika Inc Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6191148B1 (en) * 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
AU2001278755A1 (en) * 2000-08-18 2002-03-04 Takeda Chemical Industries Ltd. Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
TWI290922B (en) * 2000-12-01 2007-12-11 Takeda Chemical Industries Ltd Production method of crystals
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
JP2009504798A (ja) 2005-08-22 2009-02-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたベンゾイミダゾール誘導体
WO2007039464A1 (en) 2005-09-22 2007-04-12 Nycomed Gmbh Isotopically substituted imidazopyridine derivatives for the treatment of gastrointestinal disorders
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
AU2007256844A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
WO2008035195A1 (en) 2006-09-21 2008-03-27 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008127640A2 (en) 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008130863A2 (en) 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090076089A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched pantoprazole
US20090258897A1 (en) * 2008-04-11 2009-10-15 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268051A (zh) * 2005-07-26 2008-09-17 尼科梅德有限责任公司 同位素取代的质子泵抑制剂
CN101268050A (zh) * 2005-07-26 2008-09-17 尼科梅德有限责任公司 同位素取代的泮托拉唑

Also Published As

Publication number Publication date
CA2624179A1 (en) 2007-04-12
AU2006299424A1 (en) 2007-04-12
US7598273B2 (en) 2009-10-06
HK1124336A1 (en) 2009-07-10
JP2009511481A (ja) 2009-03-19
US20070082929A1 (en) 2007-04-12
CN101309917A (zh) 2008-11-19
EP1934201A1 (en) 2008-06-25
US20090209592A1 (en) 2009-08-20
US20090215831A1 (en) 2009-08-27
BRPI0617987A2 (pt) 2011-08-16
WO2007041630A1 (en) 2007-04-12
IL190331A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
CN101309917B (zh) 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US9422225B2 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
TW200418825A (en) Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
US20110130424A1 (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP3181554B1 (en) Quinazoline derivative
JP2009517480A5 (enExample)
US20110136914A1 (en) Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
CN101336226B (zh) 具有5-羟色胺能活性和/或去甲肾上腺素能活性的取代的苯乙胺
US20100137244A1 (en) Preparation and utility of hmg-coa reductase inhibitors
MX2008004622A (en) Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20090312435A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
CN101360742A (zh) 具有血清素源性活性和增强的治疗特性的取代苯基哌啶
HK1124336B (en) Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
HK1126751A (en) Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
HK1216635A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
HK1126774A (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124336

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1124336

Country of ref document: HK